Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 3/2014

01-09-2014 | Erratum

Erratum to: Update of Conservative Systemic Treatment of Uterine Fibroids

Authors: Magdalena Maria Zalewski, Felix Zeppernick, Joseph Neulen

Published in: Current Obstetrics and Gynecology Reports | Issue 3/2014

Login to get access

Erratum to: Curr Obstet Gynecol Rep DOI 10.1007/s13669-014-0089-4

Abstract Uterine fibroids are a common disease in women and lead to different symptoms, like pain and bleeding disorders. Apart from surgical treatment, there are many medical treatment options, which are presented in this article. Combined oral contraceptives and Levonorgestrel-releasing intrauterine systems are possible options for bleeding disorders that are a consequence of uterine fibroids. Gonadotropin-releasing hormone agonists and the new selective progesterone receptor modulator ulipristal acetate can effectively reduce myoma mass and vaginal bleeding rate. Ulipristal acetate should especially be considered for treatment in symptomatic women, as it has only a few noteworthy side effects.
Literature
1.
Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34(1):130–62.PubMedCentralPubMedCrossRef
2.
Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151:2433–42.PubMedCentralPubMedCrossRef
3.
Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and management of abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2012;85(1):35–43.PubMed
4.
Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013;14(15):2079–85.PubMedCrossRef
5.
Qin J, Yang T, Kong F, Zhou Q. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case–control studies. Arch Gynecol Obstet. 2013;288(1):139–48.PubMedCrossRef
6.
Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113–23.PubMedCentralPubMedCrossRef
7.
Wildemeersch D, Andrade A. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding. Gynecol Endocrinol. 2010;26(5):383–9.PubMedCrossRef
8.
Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand. 2012;91(1):3–9.PubMedCrossRef
9.
Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010;82(1):41–55.PubMedCrossRef
10.
Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126–30.PubMedCrossRef
11.
Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116(1):35–8.PubMedCrossRef
12.
Jindabanjerd K, Taneepanichskul S. The use of levonorgestrel—IUD in the treatment of uterine myoma in Thai women. J Med Assoc Thail. 2006;89 Suppl 4:S147–51.
13.
Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009;5(3):561–74.PubMedCentralPubMed
14.
Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002;28(2):73–7.PubMedCrossRef
15.
Alton TM, Brock GN, Yang D, Wilking DA, Hertweck SP, Loveless MB. Retrospective review of intrauterine device in adolescent and young women. J Pediatr Adolesc Gynecol. 2012;25(3):195–200.PubMedCrossRef
16.
Baldaszti E, Wimmer-Puchinger B, Löschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception. 2003;67(2):87–91.PubMedCrossRef
17.
Radesic B, Sharma A. Levonorgestrel-releasing intrauterine system for treating menstrual disorders: a patient satisfaction questionnaire. Aust N Z J Obstet Gynaecol. 2004;44(3):247–51.PubMedCrossRef
18.
Kim ML, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56(2):67–75.PubMedCentralPubMedCrossRef
19.
20.
Kiesel L, Runnebaum B. Gonadotropin–releasing–Hormon und Analoga, Physiologie und Pharmakologie. Gynakol Geburtshilfliche Rundsch. 1992;32:22–30.PubMedCrossRef
21.
Barbieri RL. Clinical applications of GnRH and its analogues. Trends Endocrinol Metab. 1992;3(1):30–4.PubMedCrossRef
22.
Minaguchi H, Wong JM, Snabes MC. Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. J Reprod Med. 2000;45(6):481–9.PubMed
23.
Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril. 1988;49(3):404–9.PubMed
24.
Kang J, YuWang D, XiaWang X. Yu J Up-regulation of apoptosis by gonadotrophin-releasing hormone agonist in cultures of endometrial cells from women with symptomatic myomas. Hum Reprod. 2010;25(9):2270–5.PubMedCrossRef
25.
Koskas M, Chabbert-Buffet N, Douvier S, Huchon C, Paganelli E, Derrien J. Role of medical treatment for symptomatic leiomyoma management in premenopausal women. J Gynecol Obstet Biol Reprod (Paris). 2011;40(8):858–74.CrossRef
26.
Talaulikar VS, Manyonda IT. Ulipristal Acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther. 2012;29(8):655–63.PubMedCrossRef
27.
Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod. 1999;14(1):44–8.PubMedCrossRef
28.
Vercellin P, Trespìdi L, Zaina B, Vicentini S, Stellato G, Crosignani PG. Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial. Fertil Steril. 2003;79(6):1390–5.CrossRef
29.
Joffe H, White DP, Crawford SL, McCurnin KE, Economou N, Connors S, et al. Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause. 2013;20(9):905–14.PubMedCrossRef
30.
Broit K. Drug-induced osteoporosis. Rev Prat. 2012;62(2):187–92.
31.
Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;4, CD001297.PubMed
32.
33.
Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(5):1129–36.PubMedCentralPubMedCrossRef
34.
Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–20.PubMedCrossRef
35.
Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–32.PubMedCrossRef
36.
Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21(4):318–24.PubMedCrossRef
37.
Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–73.PubMedCrossRef
38.
Presse-Information: Europäische Kommission erteilt Zulassung für ESMYA Typ II Variation.
Metadata
Title
Erratum to: Update of Conservative Systemic Treatment of Uterine Fibroids
Authors
Magdalena Maria Zalewski
Felix Zeppernick
Joseph Neulen
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 3/2014
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-014-0093-8

Other articles of this Issue 3/2014

Current Obstetrics and Gynecology Reports 3/2014 Go to the issue

Pelvic Organ Prolapse (KL Noblett, Section Editor)

The Past, Present and Future of POP and Physical Therapy

Management of Uterine Fibroid (I Meinhold-Heerlein, Section Editor)

Surgical Treatment of Fibroids

Pelvic Organ Prolapse (KL Noblett, Section Editor)

Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): Is There Anything New under the Sun?

Pelvic Organ Prolapse (KL Noblett, Section Editor)

An Evidence-Based Approach to the Evaluation, Diagnostic Assessment, and Treatment of Fecal Incontinence in Women

Management of Uterine Fibroid (I Meinhold-Heerlein, Section Editor)

Update of Conservative Systemic Treatment of Uterine Fibroids

Pelvic Organ Prolapse (KL Noblett, Section Editor)

Recent Developments in the Non-surgical Management of Pelvic Organ Prolapse